Hanset Nicolas, Ronco Pierre, Plaisier Emmanuelle
Unité de néphrologie, Centre hospitalier Emile-Mayrisch, Esch-sur-Alzette, Luxembourg.
Sorbonne Université, Université Pierre-et-Marie-Curie, Paris 06, et Inserm, unité mixte de recherche S1155, Paris, France - Centre de référence Maladies rares, syndrome néphrotique idiopathique - "Centre hospitalier du Mans, département de néphrologie, Le Mans, France".
Rev Prat. 2021 Jan;71(1):85-89.
"Membranous nephropathy Membranous nephropathy is the leading cause of nephrotic syndrome in adults, and results from immune complex deposition on the subepithelial surface of the glomerular basement membrane. Its outcome is unpredictable, and membranous nephropathy is associated with significant rates of kidney failure. The auto-immune nature of the disease was confirmed in the last decade with the discovery of a growing list of podocyte antigens targeted by autoantibodies, e.g. phospholipase A2 receptor (PLA2R). In the meantime, the management of patients with membranous nephropathy has changed dramatically through the evaluation of new therapeutic molecules, such as anti-B cell monoclonal antibodies, in clinical trials."
膜性肾病 膜性肾病是成人肾病综合征的主要病因，由免疫复合物沉积于肾小球基底膜上皮下表面所致。其预后难以预测，且膜性肾病与较高的肾衰竭发生率相关。在过去十年中，随着越来越多的足细胞抗原被自身抗体靶向发现，如磷脂酶A2受体（PLA2R），该疾病的自身免疫性质得到了证实。与此同时，通过在临床试验中评估新的治疗分子，如抗B细胞单克隆抗体，膜性肾病患者的治疗方式发生了巨大变化。
